vs
FrontView REIT, Inc.（FVR）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是FrontView REIT, Inc.的1.2倍（$19.6M vs $16.5M），FrontView REIT, Inc.净利率更高（-24.9% vs -177.4%，领先152.5%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
FVR vs LAB — 直观对比
营收规模更大
LAB
是对方的1.2倍
$16.5M
净利率更高
FVR
高出152.5%
-177.4%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.5M | $19.6M |
| 净利润 | $-4.1M | $-34.7M |
| 毛利率 | — | 48.5% |
| 营业利润率 | — | -168.5% |
| 净利率 | -24.9% | -177.4% |
| 营收同比 | — | -11.5% |
| 净利润同比 | — | -28.8% |
| 每股收益（稀释后） | $-0.19 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FVRLAB
| Q4 25 | $16.5M | — | ||
| Q3 25 | $16.8M | $19.6M | ||
| Q2 25 | $17.6M | $21.8M | ||
| Q1 25 | $16.2M | $40.8M | ||
| Q3 24 | $14.5M | $22.1M | ||
| Q2 24 | — | $22.5M | ||
| Q1 24 | — | $45.5M | ||
| Q4 23 | — | $28.2M |
净利润FVRLAB
| Q4 25 | $-4.1M | — | ||
| Q3 25 | $4.0M | $-34.7M | ||
| Q2 25 | $-2.9M | $-33.5M | ||
| Q1 25 | $-833.0K | $-26.0M | ||
| Q3 24 | $-2.4M | $-26.9M | ||
| Q2 24 | — | $-45.7M | ||
| Q1 24 | — | $-32.2M | ||
| Q4 23 | — | $-19.8M |
毛利率FVRLAB
| Q4 25 | — | — | ||
| Q3 25 | — | 48.5% | ||
| Q2 25 | — | 48.8% | ||
| Q1 25 | — | 48.4% | ||
| Q3 24 | — | 54.9% | ||
| Q2 24 | — | 46.1% | ||
| Q1 24 | — | 53.1% | ||
| Q4 23 | — | 47.6% |
营业利润率FVRLAB
| Q4 25 | — | — | ||
| Q3 25 | — | -168.5% | ||
| Q2 25 | — | -118.1% | ||
| Q1 25 | — | -80.8% | ||
| Q3 24 | — | -120.9% | ||
| Q2 24 | — | -134.5% | ||
| Q1 24 | — | -132.2% | ||
| Q4 23 | — | -75.9% |
净利率FVRLAB
| Q4 25 | -24.9% | — | ||
| Q3 25 | 23.9% | -177.4% | ||
| Q2 25 | -16.5% | -153.7% | ||
| Q1 25 | -5.1% | -63.8% | ||
| Q3 24 | -16.7% | -122.0% | ||
| Q2 24 | — | -203.3% | ||
| Q1 24 | — | -70.6% | ||
| Q4 23 | — | -70.2% |
每股收益（稀释后）FVRLAB
| Q4 25 | $-0.19 | — | ||
| Q3 25 | $0.19 | $-0.09 | ||
| Q2 25 | $-0.16 | $-0.09 | ||
| Q1 25 | $-0.06 | $-0.07 | ||
| Q3 24 | — | $-0.07 | ||
| Q2 24 | — | $-0.12 | ||
| Q1 24 | — | $-0.27 | ||
| Q4 23 | — | $-0.24 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $13.5M | $129.4M |
| 总债务越低越好 | $314.3M | — |
| 股东权益账面价值 | $391.2M | $399.7M |
| 总资产 | $854.4M | $539.6M |
| 负债/权益比越低杠杆越低 | 0.80× | — |
8季度趋势，按日历期对齐
现金及短期投资FVRLAB
| Q4 25 | $13.5M | — | ||
| Q3 25 | $19.6M | $129.4M | ||
| Q2 25 | $8.4M | $158.6M | ||
| Q1 25 | $3.3M | $150.9M | ||
| Q3 24 | — | $210.6M | ||
| Q2 24 | — | $269.8M | ||
| Q1 24 | — | $287.1M | ||
| Q4 23 | — | $51.7M |
总债务FVRLAB
| Q4 25 | $314.3M | — | ||
| Q3 25 | $307.1M | — | ||
| Q2 25 | $316.9M | — | ||
| Q1 25 | $310.2M | — | ||
| Q3 24 | — | $55.2M | ||
| Q2 24 | — | $55.1M | ||
| Q1 24 | — | $55.0M | ||
| Q4 23 | — | $63.5M |
股东权益FVRLAB
| Q4 25 | $391.2M | — | ||
| Q3 25 | $385.2M | $399.7M | ||
| Q2 25 | $369.9M | $424.5M | ||
| Q1 25 | $324.7M | $454.6M | ||
| Q3 24 | $1.0K | $489.3M | ||
| Q2 24 | — | $510.3M | ||
| Q1 24 | — | $577.3M | ||
| Q4 23 | — | $-148.1M |
总资产FVRLAB
| Q4 25 | $854.4M | — | ||
| Q3 25 | $846.8M | $539.6M | ||
| Q2 25 | $856.5M | $557.0M | ||
| Q1 25 | $860.8M | $579.6M | ||
| Q3 24 | $1.0K | $681.5M | ||
| Q2 24 | — | $708.7M | ||
| Q1 24 | — | $777.7M | ||
| Q4 23 | — | $323.1M |
负债/权益比FVRLAB
| Q4 25 | 0.80× | — | ||
| Q3 25 | 0.80× | — | ||
| Q2 25 | 0.86× | — | ||
| Q1 25 | 0.96× | — | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | 0.10× | ||
| Q4 23 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $42.1M | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | — | $-23.1M |
| 自由现金流率自由现金流/营收 | — | -118.1% |
| 资本支出强度资本支出/营收 | — | 4.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-111.1M |
8季度趋势，按日历期对齐
经营现金流FVRLAB
| Q4 25 | $42.1M | — | ||
| Q3 25 | $8.3M | $-22.2M | ||
| Q2 25 | $9.3M | $-20.7M | ||
| Q1 25 | $8.1M | $-30.3M | ||
| Q3 24 | — | $-27.9M | ||
| Q2 24 | — | $-39.0M | ||
| Q1 24 | — | $-62.5M | ||
| Q4 23 | — | $-14.1M |
自由现金流FVRLAB
| Q4 25 | — | — | ||
| Q3 25 | — | $-23.1M | ||
| Q2 25 | — | $-22.6M | ||
| Q1 25 | — | $-35.3M | ||
| Q3 24 | — | $-30.1M | ||
| Q2 24 | — | $-41.0M | ||
| Q1 24 | — | $-63.3M | ||
| Q4 23 | — | $-14.1M |
自由现金流率FVRLAB
| Q4 25 | — | — | ||
| Q3 25 | — | -118.1% | ||
| Q2 25 | — | -103.6% | ||
| Q1 25 | — | -86.6% | ||
| Q3 24 | — | -136.4% | ||
| Q2 24 | — | -182.2% | ||
| Q1 24 | — | -138.9% | ||
| Q4 23 | — | -50.2% |
资本支出强度FVRLAB
| Q4 25 | — | — | ||
| Q3 25 | — | 4.5% | ||
| Q2 25 | — | 8.7% | ||
| Q1 25 | — | 12.4% | ||
| Q3 24 | — | 10.2% | ||
| Q2 24 | — | 8.6% | ||
| Q1 24 | — | 1.7% | ||
| Q4 23 | — | 0.3% |
现金转化率FVRLAB
| Q4 25 | — | — | ||
| Q3 25 | 2.06× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FVR
暂无分部数据
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
